Your browser doesn't support javascript.
loading
A DNA methylation-based liquid biopsy for triple-negative breast cancer.
Cristall, Katrina; Bidard, Francois-Clement; Pierga, Jean-Yves; Rauh, Michael J; Popova, Tatiana; Sebbag, Clara; Lantz, Olivier; Stern, Marc-Henri; Mueller, Christopher R.
Afiliação
  • Cristall K; Queen's Cancer Research Institute, Queen's University, Kingston, ON, Canada.
  • Bidard FC; Department of Pathology and Molecular Medicine, Queen's University, Kingston, ON, Canada.
  • Pierga JY; Circulating Tumor Biomarkers Laboratory, SiRIC, Translational Research Department, Institut Curie, Paris, France.
  • Rauh MJ; Department of Medical Oncology, Institut Curie, Paris, France.
  • Popova T; Circulating Tumor Biomarkers Laboratory, SiRIC, Translational Research Department, Institut Curie, Paris, France.
  • Sebbag C; Department of Medical Oncology, Institut Curie, Paris, France.
  • Lantz O; Université Paris Descartes, Paris, France.
  • Stern MH; Department of Pathology and Molecular Medicine, Queen's University, Kingston, ON, Canada.
  • Mueller CR; INSERM U830 Cancer, Heterogeneity, Instability and Plasticity (CHIP), Institut Curie, Paris, France.
NPJ Precis Oncol ; 5(1): 53, 2021 Jun 16.
Article em En | MEDLINE | ID: mdl-34135468
Here, we present a next-generation sequencing (NGS) methylation-based blood test called methylation DETEction of Circulating Tumour DNA (mDETECT) designed for the optimal detection and monitoring of metastatic triple-negative breast cancer (TNBC). Based on a highly multiplexed targeted sequencing approach, this assay incorporates features that offer superior performance and included 53 amplicons from 47 regions. Analysis of a previously characterised cohort of women with metastatic TNBC with limited quantities of plasma (<2 ml) produced an AUC of 0.92 for detection of a tumour with a sensitivity of 76% for a specificity of 100%. mDETECTTNBC was quantitative and showed superior performance to an NGS TP53 mutation-based test carried out on the same patients and to the conventional CA15-3 biomarker. mDETECT also functioned well in serum samples from metastatic TNBC patients where it produced an AUC of 0.97 for detection of a tumour with a sensitivity of 93% for a specificity of 100%. An assay for BRCA1 promoter methylation was also incorporated into the mDETECT assay and functioned well but its clinical significance is currently unclear. Clonal Hematopoiesis of Indeterminate Potential was investigated as a source of background in control subjects but was not seen to be significant, though a link to adiposity may be relevant. The mDETECTTNBC assay is a liquid biopsy able to quantitatively detect all TNBC cancers and has the potential to improve the management of patients with this disease.

Texto completo: 1 Base de dados: MEDLINE Idioma: En Revista: NPJ Precis Oncol Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Canadá

Texto completo: 1 Base de dados: MEDLINE Idioma: En Revista: NPJ Precis Oncol Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Canadá